Combining Ceraxa and Vinblastine to treat difficult cases of Acute Myeloid Leukemia

Who could benefit from this research

What this research studies

This research investigates the use of Ceraxa, a ceramide nanoliposome, in combination with Vinblastine for patients suffering from relapsed or refractory Acute Myeloid Leukemia (AML). The study aims to determine the optimal dosage of Ceraxa and assess its effectiveness both alone and alongside Vinblastine. By targeting dysfunctional sphingolipid metabolism, the treatment seeks to induce cell death in cancer cells while minimizing adverse effects. Patients will be monitored for safety and efficacy as part of this innovative approach.

Why it matters

Where this research is happening

• Keystone Nano, INC.
  State College, United States Active

Researchers

• Principal investigator: Adair, Bernadette Mcmahon — Keystone Nano, INC.
• Study coordinator: Adair, Bernadette Mcmahon

Related research

Other NIH-funded projects on the same topics.

• Targeting FLT3 in relapsed or hard-to-treat acute myeloid leukemia

  This project develops immune-cell therapies that aim to attack the FLT3 protein on leukemia cells for people with relapsed or treatment-resistant acute myeloid leukemia.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11172241

• Targeting a specific protein to treat a type of blood cancer

  This study is testing a new treatment for acute myeloid leukemia (AML) using specially designed immune cells that can find and fight cancer cells with a specific protein, aiming to improve survival for patients like you.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-10894216

• Targeting the SCP4 pathway in acute myeloid leukemia (AML)

  Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11617813

• Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant

  This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11453101

• Targeting the protein housekeeping system in adult leukemia

  Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11452453

• Understanding how epigenetic helper proteins drive AML and how to target them

  A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11448341

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.